Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Ann Rheum Dis. 2023 Feb 17;82(6):829–836. doi: 10.1136/ard-2022-223792

Figure 5.

Figure 5.

Percent of cells expressing genes related to the type 1 (IFIT1, MX2, ISG15, MX1) and type 2 (IFNG, IFI30, GBP2, GBP1, PSMB8) interferon pathway in muscle biopsies from clusters ICI-DM, and ICI-MYO1 of immune checkpoint-induced myopathy compared with a representative selection of patients with other types of inflammatory myopathy (4 dermatomyositis, 3 antisynthetase syndrome, 6 immune-mediated necrotizing myositis, and 2 inclusion body myositis).